Last updated on February 2018

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: All Solid Tumors | Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other:
    Availability of tumor tissue for mesothelin expression testing
    Histologically-confirmed, mesothelin-expressing metastatic or advanced non-metastatic
    disease (tumour type specific inclusion criteria)
    At least one measurable lesion according to either Response Evaluation Criteria in
    Solid Tumors (RECIST) 1.1 or International Thymic Malignancy Interest Group (ITMIG)
    modified RECIST 1.1 as applicable
    Adequate bone marrow, liver, renal and coagulation function
    Left ventricular ejection fraction (LVEF) ≥ 50% of the lower limit of normal (LLN)
    according to local institutional ranges
    Eastern Cooperative Oncology Group (ECOG) 0 or 1

You may not be eligible for this study if the following are true:

  • More than one prior anti-tubulin/microtubule agent
    Corneal epitheliopathy or any eye disorder that may predispose the patients to this
    condition
    Symptomatic Central nervous system (CNS) metastases and/or carcinomatous meningitis
    Contraindication to both CT and MRI contrast agents
    Active hepatitis B or C infection
    Pregnant or breast-feeding patients
    Tumor type specific exclusion criteria

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.